Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483423 | 0.92 | NR1H4 (0.42) | NR1H4KCNH2P2RX3CNR1PTGER1 | |
| SCHEMBL1482749 | 0.91 | P2RX3 (0.43) | NR1H4KCNH2P2RX3CNR1PTGER1 | |
| SCHEMBL1482645 | 0.91 | NR1H4 (0.48) | NR1H4KCNH2TBXA2RPTGER1 | |
| SCHEMBL1482376 | 0.90 | DRD2 (0.47) | NR1H4KCNH2TBXA2RDRD2P2RX3 | |
| SCHEMBL1483050 | 0.89 | KDM4E (0.43) | NR1H4TBXA2RDRD2P2RX3SCN7A | |
| SCHEMBL1482639 | 0.88 | NR1H4 (0.49) | NR1H4KCNH2P2RX3CNR1PTGER1 | |
| SCHEMBL1482104 | 0.88 | PTGER1 (0.45) | NR1H4KCNH2PTGER1CYP3A4CYP2D6 | |
| SCHEMBL1482801 | 0.87 | TBXA2R (0.44) | NR1H4TBXA2RDRD2P2RX3CNR1 | |
| SCHEMBL1482284 | 0.86 | NR1H4 (0.49) | NR1H4KCNH2TBXA2RP2RX3PTGER1 | |
| SCHEMBL1482458 | 0.86 | PTGER1 (0.43) | NR1H4KCNH2TBXA2RDRD2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885KCNH2 839/4885TBXA2R 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.